Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences

por Yao, Shuyang, Meric-Bernstam, Funda, Hong, David, Janku, Filip, Naing, Aung, Piha-Paul, Sarina Anne, Tsimberidou, Apostolia Maria, Karp, Daniel, Subbiah, Vivek, Yap, Timothy Anthony, Ahnert, Jordi Rodon, Pant, Shubham, Dumbrava, Ecaterina E Ileana, Wathoo, Chetna, Campbell, Erick, Yu, Lihou, Yamamura, Yuko, Fu, Siqing
Publicado 2022

Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications

por Dumbrava, Ecaterina E. Ileana, Balaji, Kavitha, Raghav, Kanwal, Hess, Kenneth, Javle, Milind, Blum-Murphy, Mariela, Ajani, Jaffer, Kopetz, Scott, Broaddus, Russell, Routbort, Mark, Demirhan, Mehmet, Zheng, Xiaofeng, Pant, Shubham, Tsimberidou, Apostolia M., Subbiah, Vivek, Hong, David S., Rodon, Jordi, Shaw, Kenna M., Piha-Paul, Sarina A., Meric-Bernstam, Funda
Publicado 2019

Phase 2 study of pembrolizumab in patients with advanced rare cancers

por Naing, Aung, Meric-Bernstam, Funda, Stephen, Bettzy, Karp, Daniel D, Hajjar, Joud, Rodon Ahnert, Jordi, Piha-Paul, Sarina A, Colen, Rivka R, Jimenez, Camilo, Raghav, Kanwal P, Ferrarotto, Renata, Tu, Shi-Ming, Campbell, Matthew, Wang, Linghua, Sabir, Sarjeel H, Tapia, Coya, Bernatchez, Chantale, Frumovitz, Michael, Tannir, Nizar, Ravi, Vinod, Khan, Saria, Painter, Jeane M, Abonofal, Abulrahman, Gong, Jing, Alshawa, Anas, McQuinn, Lacey M, Xu, Mingxuan, Ahmed, Sara, Subbiah, Vivek, Hong, David S, Pant, Shubham, Yap, Timothy A, Tsimberidou, Apostolia M, Dumbrava, Ecaterina E Ileana, Janku, Filip, Fu, Siqing, Simon, Richard M, Hess, Kenneth R, Varadhachary, Gauri R, Amir Habra, Mouhammed
Publicado 2020